24/7 Market News Snapshot 25 July, 2025 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)
DENVER, Colo., 25 July, 2025 (www.247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. (PHIO) has captured attention in the market today, with its stock experiencing a notable surge, opening at $3.02 and reaching a current trading value of $3.025, reflecting an impressive increase of over 20.52% from a previous close of $2.51. The dramatic rise has been accompanied by a significant trading volume of 43.29 million shares, indicating heightened investor interest and enthusiasm for the company’s potential trajectory.
This revitalized market momentum coincides with positive developments in Phio Pharmaceuticals’ clinical endeavors, particularly regarding its novel cancer treatment, PH-762. The company has unveiled promising preliminary results from its Phase 1b clinical trial, which focuses on the treatment of challenging skin cancers through its proprietary INTASYL® gene silencing technology. Among the most striking outcomes, a patient with cutaneous squamous cell carcinoma (cSCC) achieved a complete pathological response, showcasing 100% tumor clearance. Furthermore, another patient suffering from metastatic Merkel cell carcinoma exhibited a partial response, with over 50% tumor reduction.
The trial has thus far enrolled 15 patients, demonstrating the safety and efficacy of PH-762, which has shown no dose-limiting toxicities or serious adverse effects, reflecting excellent tolerability among participants. In total, the program has recorded five complete responses, one near-complete response, and one partial response in patients with cSCC, underscoring the therapy’s potential as an effective non-surgical alternative for patients.
Phio’s CEO and Chairman, Robert Bitterman, expressed optimism regarding the findings, emphasizing the company’s commitment to advancing innovative cancer treatment solutions. As Phio Pharmaceuticals seeks participants for the final cohort of the trial, the developments indicate a pivotal moment in the firm’s growth and its efforts to enhance therapeutic options in the field of immuno-oncology.